Together, these results suggest that despite elevated replication initiation, the reduction in viability upon combined treatment with WEE1 and ATR inhibitors cannot simply be explained by an increased induction of S-phase DNA damage in the lung cancer cells. This evidence concerns the gene WEE1 and lung carcinoma.